In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $12.74.
Biegler covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Nurix Therapeutics, and Fate Therapeutics. According to TipRanks, Biegler has an average return of 3.2% and a 38.51% success rate on recommended stocks.
Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $17.40.
See Insiders’ Hot Stocks on TipRanks >>
ORIC market cap is currently $791.5M and has a P/E ratio of -6.38.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ORIC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oric Pharmaceuticals (ORIC) Company Description:
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
Read More on ORIC:
- Oric Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
